- Email: [email protected]
Millipore enhances Millex product line
NEWS Editorial Office: Elsevier Ltd P O Box 150, Kidlington Oxford OX5 1AS, UK Tel: +44 (0)1865 843239 Fax: +44 (0)1865 843971 E-mail: [email protected]
Editor: Steve Barrett
Contributing Editor: Simon Atkinson Tel/Fax: +44 (0)1865 751611 Email: [email protected]. com
Production Controller: Russell Purdy Editorial advisory board: Dr P Ball (Pall Europe), Dr D Bessarabov (Ballard Power Systems), Prof. M Cheryan (University of Illinois at Urbana-Champaign), Prof. A Fane (University of New South Wales), Dr T Franken (Membrane Application Centre Twente), Prof. E Gobina (Robert Gordon University), Dr A Merry (Aquious–PCI Membranes), Prof. M Nyström (Lappeenranta University of Technology), Dr G Pearce (Kalsep), Dr P Pfromm (Institute of Paper Science & Technology, GA, USA), Dr R Philpott (Whatman International), Dr A Turner (Alchimista Consulting Ltd), Prof. R Wakeman (Loughborough University of Technology), Prof. A Yaroshchuk (Ukrainian Academy of Sciences). Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: permissions@ elsevier.com. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then ‘Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0) 171 436 5931; fax: +44 (0)171 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02095 Printed by Mayfield Press (Oxford) Ltd.
2
Kruger selects Norit X-Flow Kruger Inc, a Veolia Water Solutions & Technologies company, has selected Norit X-Flow as an alliance partner to offer its ultrafiltration systems and products to markets in the USA and Canada. Kruger’s President, Mike Gutshall, said: ‘We believe that membrane technologies will continue to grow and play an even more significant role in water and wastewater treatment throughout the USA. In response to the expected increase in membrane needs, Kruger has teamed up with quality membrane manufacturers, such as Norit X-Flow, to supply membrane systems and products to the US market. Our goal is to have the appropriate systems and products that meet our client’s current and future needs.’ With over 25 years of experience in research and product development, Norit X-Flow is one of the world’s leading suppliers of membrane technology. It has achieved great success, and has been a dominant membrane provider in Europe, Asia and the Middle East with a installed capacity of over 3000 million litres (800 million gallons) per day. Rick Rosberg, Global Director of Marketing and Sales at Norit X-Flow, commented: ‘We are proud that one of the largest suppliers of water systems in the world has selected Norit X-Flow. By joining forces we are confident that we can establish a leading position in the US and Canadian water market.’ Kruger says that it will supply Norit X-Flow membranes not only as standalone products but also as a system combined with other processes. Contacts: I. Kruger Inc, 401 Harrison Oaks Boulevard, Suite 100, Cary, NC 27513, USA. Tel: +1 919 677 8310, www.krugerusa.com X-Flow BV, Marssteden 50, NL-7547 TC Enschede, The Netherlands. Tel: +31 53 428 7350, www.norit.com
Millipore enhances Millex product line Millipore Corporation of Billerica, Massachusetts, USA, is offering a
range of syringe filters, with nylon membranes, for analytical sample preparation. These non-sterile, Millex syringe filters are used for the filtration of 10–100 ml aqueous and mild organic solutions prior to high performance liquid chromatography (HPLC), or other instrument analysis. The filters are available with membranes that have pore sizes of 0.20 µm and 0.45 µm, and deliver fast filter rates for high throughput. The company says that these products are the latest addition to its expanding line of 33 mm syringe filters, which includes devices with Durapore (polyvinylidene difluoride) and Millipore Express PLUS (polyethersulfone) membranes. The Millex syringe filter’s colour-coded, over-moulded design allows the unit to operate at a pressure of around 0.7 MPa (100 psig), which contributes to the unit’s fast flow rate. In addition, the hold-up volume is 20% less than that of standard 25-mm syringe filters. Contact: Millipore Corporation, 290 Concord Road, Billerica, MA 01821, USA. Tel: +1 978 715 4321, www.millipore.com
Pall posts strong sales and earnings US-based Pall Corporation has posted strong sales and earnings results for its second quarter ended 31 January 2007. Sales for the quarter totalled $544.9 million — up 13.9% compared with the second quarter of 2006. Net earnings were $55.8 million compared with $32.4 million a year earlier. For the six-month period ended 31 January 2007 sales totalled $1.04 billion, which represents an increase of 14.8% compared with the figure posted for corresponding period of the previous financial year. Net earnings for the first six months of fiscal 2007 amounted to $80.2 million. ‘Sales growth was strong in Industrial and Life Sciences, driven by our Total Fluid Management
strategy and leading position in fastgrowing markets. Improvements in productivity and our well-established cost-reduction initiatives were the real stars of the quarter. Our six-month operating profit growth of 33% demonstrates that Pall is successfully executing its profit improvement efforts,’ said Eric Krasnoff, the company’s Chairman and Chief Executive Officer. Pall says that in its Life Sciences segment biopharmaceuticals sales reflect the continued adoption of its technologies throughout the fast-growing biotechnology and vaccine industries. Medical sales increased — driven by new bloodcentre customers, and new products and applications for the blood business, and growth in the hospital and bio-sciences markets. Laboratory products experienced growth of over 11% on top of a strong performance for the equivalent quarter of fiscal 2006. General industrial systems sales growth in the municipal water and energy markets was particularly strong, says the company. Microelectronics sales continue to benefit from Pall’s strategic diversification into the consumer side of the electronics market. Sales in Asia were robust while the US market started to slow during the quarter. In its Life Sciences segment the company continues to expect mid single-digit sales growth in fiscal 2007 with medical sales growth abating in the second half of the year and biopharmaceuticals achieving low double-digit growth for the year. Pall Industrial sales are expected to modestly surpass the 5–7% growth range provided at the beginning of the fiscal year, reflecting a slowdown in microelectronics and the consistent vitality of the systems business. Contact: Pall Corporation, 2200 Northern Boulevard, East Hills, NY 11548, USA. Tel: +1 516 484 5400, www.pall.com
Aqua-Aerobic Systems uses Puron modules In the USA, Aqua-Aerobic Systems Inc, which designs and manufactures wastewater
Membrane Technology May 2007
Editor: Steve Barrett
Contributing Editor: Simon Atkinson Tel/Fax: +44 (0)1865 751611 Email: [email protected]. com
Production Controller: Russell Purdy Editorial advisory board: Dr P Ball (Pall Europe), Dr D Bessarabov (Ballard Power Systems), Prof. M Cheryan (University of Illinois at Urbana-Champaign), Prof. A Fane (University of New South Wales), Dr T Franken (Membrane Application Centre Twente), Prof. E Gobina (Robert Gordon University), Dr A Merry (Aquious–PCI Membranes), Prof. M Nyström (Lappeenranta University of Technology), Dr G Pearce (Kalsep), Dr P Pfromm (Institute of Paper Science & Technology, GA, USA), Dr R Philpott (Whatman International), Dr A Turner (Alchimista Consulting Ltd), Prof. R Wakeman (Loughborough University of Technology), Prof. A Yaroshchuk (Ukrainian Academy of Sciences). Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: permissions@ elsevier.com. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then ‘Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0) 171 436 5931; fax: +44 (0)171 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02095 Printed by Mayfield Press (Oxford) Ltd.
2
Kruger selects Norit X-Flow Kruger Inc, a Veolia Water Solutions & Technologies company, has selected Norit X-Flow as an alliance partner to offer its ultrafiltration systems and products to markets in the USA and Canada. Kruger’s President, Mike Gutshall, said: ‘We believe that membrane technologies will continue to grow and play an even more significant role in water and wastewater treatment throughout the USA. In response to the expected increase in membrane needs, Kruger has teamed up with quality membrane manufacturers, such as Norit X-Flow, to supply membrane systems and products to the US market. Our goal is to have the appropriate systems and products that meet our client’s current and future needs.’ With over 25 years of experience in research and product development, Norit X-Flow is one of the world’s leading suppliers of membrane technology. It has achieved great success, and has been a dominant membrane provider in Europe, Asia and the Middle East with a installed capacity of over 3000 million litres (800 million gallons) per day. Rick Rosberg, Global Director of Marketing and Sales at Norit X-Flow, commented: ‘We are proud that one of the largest suppliers of water systems in the world has selected Norit X-Flow. By joining forces we are confident that we can establish a leading position in the US and Canadian water market.’ Kruger says that it will supply Norit X-Flow membranes not only as standalone products but also as a system combined with other processes. Contacts: I. Kruger Inc, 401 Harrison Oaks Boulevard, Suite 100, Cary, NC 27513, USA. Tel: +1 919 677 8310, www.krugerusa.com X-Flow BV, Marssteden 50, NL-7547 TC Enschede, The Netherlands. Tel: +31 53 428 7350, www.norit.com
Millipore enhances Millex product line Millipore Corporation of Billerica, Massachusetts, USA, is offering a
range of syringe filters, with nylon membranes, for analytical sample preparation. These non-sterile, Millex syringe filters are used for the filtration of 10–100 ml aqueous and mild organic solutions prior to high performance liquid chromatography (HPLC), or other instrument analysis. The filters are available with membranes that have pore sizes of 0.20 µm and 0.45 µm, and deliver fast filter rates for high throughput. The company says that these products are the latest addition to its expanding line of 33 mm syringe filters, which includes devices with Durapore (polyvinylidene difluoride) and Millipore Express PLUS (polyethersulfone) membranes. The Millex syringe filter’s colour-coded, over-moulded design allows the unit to operate at a pressure of around 0.7 MPa (100 psig), which contributes to the unit’s fast flow rate. In addition, the hold-up volume is 20% less than that of standard 25-mm syringe filters. Contact: Millipore Corporation, 290 Concord Road, Billerica, MA 01821, USA. Tel: +1 978 715 4321, www.millipore.com
Pall posts strong sales and earnings US-based Pall Corporation has posted strong sales and earnings results for its second quarter ended 31 January 2007. Sales for the quarter totalled $544.9 million — up 13.9% compared with the second quarter of 2006. Net earnings were $55.8 million compared with $32.4 million a year earlier. For the six-month period ended 31 January 2007 sales totalled $1.04 billion, which represents an increase of 14.8% compared with the figure posted for corresponding period of the previous financial year. Net earnings for the first six months of fiscal 2007 amounted to $80.2 million. ‘Sales growth was strong in Industrial and Life Sciences, driven by our Total Fluid Management
strategy and leading position in fastgrowing markets. Improvements in productivity and our well-established cost-reduction initiatives were the real stars of the quarter. Our six-month operating profit growth of 33% demonstrates that Pall is successfully executing its profit improvement efforts,’ said Eric Krasnoff, the company’s Chairman and Chief Executive Officer. Pall says that in its Life Sciences segment biopharmaceuticals sales reflect the continued adoption of its technologies throughout the fast-growing biotechnology and vaccine industries. Medical sales increased — driven by new bloodcentre customers, and new products and applications for the blood business, and growth in the hospital and bio-sciences markets. Laboratory products experienced growth of over 11% on top of a strong performance for the equivalent quarter of fiscal 2006. General industrial systems sales growth in the municipal water and energy markets was particularly strong, says the company. Microelectronics sales continue to benefit from Pall’s strategic diversification into the consumer side of the electronics market. Sales in Asia were robust while the US market started to slow during the quarter. In its Life Sciences segment the company continues to expect mid single-digit sales growth in fiscal 2007 with medical sales growth abating in the second half of the year and biopharmaceuticals achieving low double-digit growth for the year. Pall Industrial sales are expected to modestly surpass the 5–7% growth range provided at the beginning of the fiscal year, reflecting a slowdown in microelectronics and the consistent vitality of the systems business. Contact: Pall Corporation, 2200 Northern Boulevard, East Hills, NY 11548, USA. Tel: +1 516 484 5400, www.pall.com
Aqua-Aerobic Systems uses Puron modules In the USA, Aqua-Aerobic Systems Inc, which designs and manufactures wastewater
Membrane Technology May 2007